AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

上周五，英国制药巨头阿斯利康（AstraZeneca, NASDAQ:AZN）宣布与中国石药集团（CSPC Pharmaceutical）达成一项潜在价值高达53.3亿美元的战略研究合作，旨在利用人工智能（AI）开发针对多种慢性疾病的新型口服疗法。

AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the ...

The deal with China’s CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of ...

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

The collaboration will focus on identifying pre-clinical candidates for high-priority targets, including a small molecule ...

Friday’s deal with fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in China.

AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth ...

CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...

Cambridge: AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group ...

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.